Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Sepsis Diagnostics Market Expected to Grow Between 2025 And 2029?

In the past few years, the sepsis diagnostics market has witnessed robust growth. The market size is projected to expand from $0.99 billion in 2024 to $1.07 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The growth observed in the historical period can be credited to the increasing occurrences of sepsis, heightened awareness regarding early detection, escalating healthcare costs, rising incidences of hospital-acquired infections, and the growing acceptance of point-of-care testing.

The market for sepsis diagnostics is anticipated to experience substantial expansion in the forthcoming years, possibly reaching an estimated $1.46 billion by 2029 with an 8.1% compound annual growth rate (CAGR). This growth during the forecast period can be ascribed to a variety of contributing factors which include the escalating demand for swift diagnostic methods, the augmentation of investment in healthcare infrastructure, a rising emphasis on individualized medicine, a growing prevalence in antimicrobial resistance and the increased utilization of next-generation sequencing. Dominant trends within the forecast period exhibit the incorporation of AI within diagnostics, ongoing improvement in biomarker technology, advancement in the field of molecular diagnostics, a transition towards automated and digital diagnostic systems, and the continued progression of artificial intelligence within diagnostics.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23514&type=smp

Which Factors and External Forces Are Driving Demand in the Sepsis Diagnostics Market?

The escalating occurrence of infections attained within hospitals is projected to drive the expansion of the sepsis diagnostics market in the future. Infections that are acquired in hospitals, also known as Hospital-Acquired Infections (HAIs), usually develop during or following a patient’s visit to the hospital, typically after 48 hours of admission and were not present in the patient upon admission. The escalation in occurrences of such infections is as a result of the growing resistance to antibiotics. Excessive and inappropriate use of antibiotics within healthcare environments has given rise to bacteria that are resistant to treatments, complicating the treatment process. With the use of sepsis diagnostics, these infections can be detected at an early stage by identifying the pathogens and biomarkers, enabling immediate treatment and reducing the likelihood of complications. For example, data from the Australian Institute of Health and Welfare, a government agency based in Australia, shows that in 2022-23, hospital-acquired infections were observed in 2% of public hospital admissions and 0.8% of private hospital admissions, with infections associated with healthcare being the most common complication. Consequently, the escalating occurrence of hospital-acquired infections is fuelling growth in the sepsis diagnostics market.

Which Segments in the Sepsis Diagnostics Offer the Most Growth?

The sepsis diagnosticsmarket covered in this report is segmented –

1) By Product: Instruments; Blood Culture Media; Assay Kits And Reagents; Software

2) By Technology: Microbiology; Molecular Diagnostics; Immunoassays; Flow Cytometry; Other Technologies

3) By Pathogen: Bacterial Sepsis; Fungal Sepsis; Viral Sepsis; Other Pathogens

4) By Method: Automated Diagnostics; Conventional Diagnostics

5) By End-Users: Hospitals And Clinics; Pathology And Reference Laboratories; Research Institutes

Subsegments:

1) By Instruments: Automated Analyzers; Point-Of-Care (PoC) Testing Devices; Microfluidic-Based Devices; Polymerase Chain Reaction (PCR) Instruments; Flow Cytometers

2) By Blood Culture Media: Aerobic Blood Culture Media; Anaerobic Blood Culture Media; Mycobacteria Blood Culture Media; Pediatric Blood Culture Media; Fungal Blood Culture Media

3) By Assay Kits And Reagents: Enzyme-Linked Immunosorbent Assay (ELISA) Kits; Polymerase Chain Reaction (PCR) Assay Kits; Immunoassay Reagents; Molecular Diagnostic Reagents; Biosensor-Based Assay Kits

4) By Software: Data Management Software; Laboratory Information Systems (LIS); Artificial Intelligence (AI)-Based Diagnostic Tools; Predictive Analytics Software; Cloud-Based Diagnostic Platforms

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23514&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Sepsis Diagnostics Market?# Market?

North America was the largest region in the sepsis diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sepsis diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theSepsis Diagnostics Market’s Growth?

Leading firms in the sepsis diagnostics market are concentrating on the evolution of innovative solutions, such as culture-free diagnostic tools, aimed at expediting the accurate diagnosis of sepsis sans the dependency on traditional blood cultures. Culture-free diagnostic tools refer to methods utilized for identifying infections or pathogens without resorting to standard microbial culture procedures. These solutions look to cutting-edge technologies such as PCR, NGS or immunoassays for swiftly recognizing pathogens straight from a patient’s body, be it through blood, saliva or tissue samples. As an illustration, in April 2024, Deepull Diagnostics S.L., a manufacturer based in Spain, rolled out the UllCORE diagnostic infrastructure specifically crafted for the early detection of sepsis. This sophisticated system, engineered by Deepull, is a benchtop, culture-free multiplex PCR platform designed for the immediate recognition of pathogens prevalent in sepsis and similar acute infections. The system separates microbial DNA from 8mL of whole blood and delivers 50 reportable outcomes within an hour. Able to detect 95% of bacteria, fungi, and antibiotic-resistant genes causing sepsis, the UllCORE system is designed to enhance early diagnosis and diminish the misappropriation of antibiotics. UllCORE aids hospitals in their fight against the growing problem of antimicrobial resistance.

View the full report here:

https://www.thebusinessresearchcompany.com/report/sepsis-diagnostics-global-market-report

What Are the Key Elements That Define the Sepsis Diagnostics Market?

Sepsis diagnostics refers to a range of advanced technologies and tests designed to quickly detect the presence of sepsis, a critical condition that can lead to organ failure and death if left untreated. These technologies enable healthcare providers to assess the severity of the condition and make timely, informed decisions to initiate appropriate treatment and improve patient survival rates.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23514

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model